Abstract 3721: Critical role of Bevacizumab schedule in combination with chemo-radiotherapy in neo-adjuvant treatment of rectal cancer: Circulating endothelial cells and FDG-PET as markers for early prediction
Antonio Avallone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alfredo Budillon(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Paolo Delrio(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Elena Di Gennaro(Istituto Giannina Gaslini), Alessandra Leone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Secondo Lastoria(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Corradina Caracò(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Pasquale Comella(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Luigi Aloi(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Maria Chianese(University of Trieste), Rosario V. Iaffaioli(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Biagio Pecori(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cited by 0
Related Papers
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k
Cancer classification using the Immunoscore: a worldwide task force
|Journal of Translational Medicine|2012|803
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study
|The Lancet. Gastroenterology & hepatology|2024|245
Emerging anti-cancer molecular mechanisms of aminobisphosphonates
|Endocrine Related Cancer|2006|131
Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation
|Journal of Experimental & Clinical Cancer Research|2019|125